Bedrosian Camille L, Chief Medical Officer of Amylyx Pharmaceuticals ($AMLX), sold common shares on the open market four times in the last 365 days for a total of $407 thousand. Her most recent sale occurred on March 2, 2026. These transactions rank her 6,905th among 11,678 individual insiders by sale value, well below the average of 8.6 million per insider across 6.4 transactions. She reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Common Stock | 95990 | $0.00 | 265,285.0000 | 109,819,569 | 56.70% | 0.09% |
| March 5, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Stock Option (Right to Buy) | 143985 | $0.00 | 143,985.0000 | 109,819,569 | 9999.99% | 0.13% |
| March 2, 2026 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | S | Common Stock | 6461 | $14.58 | 169,295.0000 | 109,819,569 | 3.68% | 0.01% |
| Dec. 1, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | S | Common Stock | 6580 | $14.35 | 175,756.0000 | 109,819,569 | 3.61% | 0.01% |
| Sept. 30, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | S | Common Stock | 12039 | $14.58 | 182,336.0000 | 88,602,468 | 6.19% | 0.01% |
| June 24, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | A | Stock Option (right to buy) | 7037 | $0.00 | 7,037.0000 | 63,059,165 | 9999.99% | 0.01% |
| June 24, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | A | Restricted Stock Units | 4712 | $0.00 | 4,712.0000 | 63,059,165 | 9999.99% | 0.01% |
| June 18, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | M | Common Stock | 4000 | $0.00 | 7,000.0000 | 63,059,165 | 133.33% | 0.01% |
| June 18, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | M | Restricted Stock Units | 4000 | $0.00 | 0.0000 | 63,059,165 | 100.00% | 0.01% |
| June 11, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Bedrosian Camille L | Not found | A | Common Stock | 6900 | $0.00 | 16,300.0000 | 92,926,000 | 73.40% | 0.01% |
| June 11, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Bedrosian Camille L | Not found | A | Stock Option (right to buy) | 10350 | $0.00 | 10,350.0000 | 92,926,000 | 9999.99% | 0.01% |
| March 31, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | S | Common Stock | 12425 | $3.47 | 194,375.0000 | 88,602,468 | 6.01% | 0.01% |
| March 6, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Common Stock | 68420 | $0.00 | 206,800.0000 | 88,602,468 | 49.44% | 0.08% |
| March 6, 2025 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Stock Option (Right to Buy) | 102630 | $0.00 | 102,630.0000 | 88,602,468 | 9999.99% | 0.12% |
| Dec. 2, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | S | Common Stock | 5421 | $5.54 | 138,380.0000 | 0 | 3.77% | 0.00% |
| Sept. 30, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | S | Common Stock | 11442 | $3.20 | 143,801.0000 | 0 | 7.37% | 0.00% |
| June 21, 2024 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | M | Restricted Stock Units | 3000 | $0.00 | 0.0000 | 60,143,558 | 100.00% | 0.00% |
| June 21, 2024 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | M | Common Stock | 3000 | $0.00 | 3,000.0000 | 60,143,558 | 9999.99% | 0.00% |
| June 18, 2024 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | A | Stock Option (right to buy) | 14000 | $0.00 | 14,000.0000 | 60,143,558 | 9999.99% | 0.02% |
| June 18, 2024 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | A | Restricted Stock Units | 4000 | $0.00 | 4,000.0000 | 60,143,558 | 9999.99% | 0.01% |
| June 7, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Bedrosian Camille L | Not found | A | Common Stock | 3400 | $0.00 | 9,400.0000 | 68,175,000 | 56.67% | 0.00% |
| June 7, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Bedrosian Camille L | Not found | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 68,175,000 | 9999.99% | 0.02% |
| April 16, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Stock Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 0 | 9999.99% | 0.00% |
| April 16, 2024 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Common Stock | 96910 | $0.00 | 155,243.0000 | 0 | 166.13% | 0.00% |
| Nov. 27, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Common Stock | 58333 | $0.00 | 58,333.0000 | 0 | 9999.99% | 0.00% |
| Nov. 27, 2023 | Amylyx Pharmaceuticals, Inc. | $AMLX | Bedrosian Camille L | Chief Medical Officer | A | Stock Option (Right to Buy) | 162500 | $0.00 | 162,500.0000 | 0 | 9999.99% | 0.00% |
| June 21, 2023 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | A | Stock Option (right to buy) | 14000 | $0.00 | 14,000.0000 | 56,708,975 | 9999.99% | 0.02% |
| June 21, 2023 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Bedrosian Camille L | Director | A | Restricted Stock Units | 3000 | $0.00 | 3,000.0000 | 56,708,975 | 9999.99% | 0.01% |
| June 16, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Bedrosian Camille L | Director | A | Common Stock | 6000 | $0.00 | 6,000.0000 | 0 | 9999.99% | 0.00% |
| June 16, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Bedrosian Camille L | Director | A | Stock Option (right to buy) | 17500 | $0.00 | 17,500.0000 | 0 | 9999.99% | 0.00% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Bedrosian Camille L | EVP and Chief Medical Officer | S | Common Stock | 3881 | $45.25 | 46,720.0000 | 69,914,225 | 7.67% | 0.01% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Bedrosian Camille L | EVP and Chief Medical Officer | A | Common Stock | 2663 | $0.00 | 50,601.0000 | 69,914,225 | 5.56% | 0.00% |